nodes	percent_of_prediction	percent_of_DWPC	metapath
Orlistat—Gingival disorder—Cyclosporine—focal segmental glomerulosclerosis	0.0561	0.129	CcSEcCtD
Orlistat—PLA2G7—Lissencephaly gene (LIS1) in neuronal migration and development—VLDLR—focal segmental glomerulosclerosis	0.0533	0.0993	CbGpPWpGaD
Orlistat—LIPF—Triacylglyceride Synthesis—LIPC—focal segmental glomerulosclerosis	0.0431	0.0802	CbGpPWpGaD
Orlistat—LIPF—Fatty Acid Beta Oxidation—LIPC—focal segmental glomerulosclerosis	0.0326	0.0607	CbGpPWpGaD
Orlistat—Unspecified disorder of autonomic nervous system—Cyclosporine—focal segmental glomerulosclerosis	0.0276	0.0635	CcSEcCtD
Orlistat—LIPF—Triacylglyceride Synthesis—LPL—focal segmental glomerulosclerosis	0.0263	0.049	CbGpPWpGaD
Orlistat—Autonomic neuropathy—Cyclosporine—focal segmental glomerulosclerosis	0.0233	0.0536	CcSEcCtD
Orlistat—DAGLA—Effects of PIP2 hydrolysis—TRPC6—focal segmental glomerulosclerosis	0.0212	0.0396	CbGpPWpGaD
Orlistat—DAGLB—Effects of PIP2 hydrolysis—TRPC6—focal segmental glomerulosclerosis	0.0212	0.0396	CbGpPWpGaD
Orlistat—LIPF—Fatty Acid Beta Oxidation—LPL—focal segmental glomerulosclerosis	0.0199	0.037	CbGpPWpGaD
Orlistat—Bullous eruption—Cyclosporine—focal segmental glomerulosclerosis	0.0134	0.0308	CcSEcCtD
Orlistat—Nephropathy—Cyclosporine—focal segmental glomerulosclerosis	0.0111	0.0256	CcSEcCtD
Orlistat—PNLIP—Lipid and lipoprotein metabolism—LIPC—focal segmental glomerulosclerosis	0.0104	0.0194	CbGpPWpGaD
Orlistat—DAGLB—kidney—focal segmental glomerulosclerosis	0.0103	0.357	CbGeAlD
Orlistat—PLA2G7—IL1 and megakaryotyces in obesity—MMP9—focal segmental glomerulosclerosis	0.00917	0.0171	CbGpPWpGaD
Orlistat—Multiple fractures—Cyclosporine—focal segmental glomerulosclerosis	0.0091	0.0209	CcSEcCtD
Orlistat—Fracture—Cyclosporine—focal segmental glomerulosclerosis	0.0091	0.0209	CcSEcCtD
Orlistat—Gastrointestinal symptom NOS—Cyclosporine—focal segmental glomerulosclerosis	0.009	0.0207	CcSEcCtD
Orlistat—PLA2G7—Peptide hormone metabolism—ACE—focal segmental glomerulosclerosis	0.00894	0.0166	CbGpPWpGaD
Orlistat—Nail disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00816	0.0188	CcSEcCtD
Orlistat—Tooth disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00816	0.0188	CcSEcCtD
Orlistat—DAGLA—Platelet activation, signaling and aggregation—ACTN4—focal segmental glomerulosclerosis	0.00774	0.0144	CbGpPWpGaD
Orlistat—DAGLB—Platelet activation, signaling and aggregation—ACTN4—focal segmental glomerulosclerosis	0.00774	0.0144	CbGpPWpGaD
Orlistat—ABHD16A—cortex of kidney—focal segmental glomerulosclerosis	0.00758	0.263	CbGeAlD
Orlistat—PNLIP—Retinoid metabolism and transport—LPL—focal segmental glomerulosclerosis	0.00745	0.0139	CbGpPWpGaD
Orlistat—ABHD12—cortex of kidney—focal segmental glomerulosclerosis	0.00711	0.247	CbGeAlD
Orlistat—PNLIP—Lipid and lipoprotein metabolism—LPL—focal segmental glomerulosclerosis	0.00636	0.0118	CbGpPWpGaD
Orlistat—Acne—Cyclosporine—focal segmental glomerulosclerosis	0.00629	0.0145	CcSEcCtD
Orlistat—Cardiovascular disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00602	0.0139	CcSEcCtD
Orlistat—Amenorrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.00602	0.0139	CcSEcCtD
Orlistat—Rectal haemorrhage—Cyclosporine—focal segmental glomerulosclerosis	0.00586	0.0135	CcSEcCtD
Orlistat—Arthropathy—Cyclosporine—focal segmental glomerulosclerosis	0.00582	0.0134	CcSEcCtD
Orlistat—Dysmenorrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.00582	0.0134	CcSEcCtD
Orlistat—FASN—p73 transcription factor network—WT1—focal segmental glomerulosclerosis	0.00574	0.0107	CbGpPWpGaD
Orlistat—PLA2G7—Peptide hormone metabolism—AGT—focal segmental glomerulosclerosis	0.00566	0.0106	CbGpPWpGaD
Orlistat—Eructation—Cyclosporine—focal segmental glomerulosclerosis	0.0052	0.012	CcSEcCtD
Orlistat—Cramps of lower extremities—Cyclosporine—focal segmental glomerulosclerosis	0.00486	0.0112	CcSEcCtD
Orlistat—Neoplasm—Cyclosporine—focal segmental glomerulosclerosis	0.00478	0.011	CcSEcCtD
Orlistat—Urine output increased—Cyclosporine—focal segmental glomerulosclerosis	0.00478	0.011	CcSEcCtD
Orlistat—PLA2G4A—ADP signalling through P2Y purinoceptor 1—GNAQ—focal segmental glomerulosclerosis	0.00447	0.00832	CbGpPWpGaD
Orlistat—Diabetes mellitus—Cyclosporine—focal segmental glomerulosclerosis	0.00441	0.0102	CcSEcCtD
Orlistat—Polyuria—Cyclosporine—focal segmental glomerulosclerosis	0.00437	0.0101	CcSEcCtD
Orlistat—Hepatic failure—Cyclosporine—focal segmental glomerulosclerosis	0.00427	0.00983	CcSEcCtD
Orlistat—Eczema—Cyclosporine—focal segmental glomerulosclerosis	0.00427	0.00983	CcSEcCtD
Orlistat—DAGLB—G alpha (q) signalling events—TRPC6—focal segmental glomerulosclerosis	0.00425	0.00791	CbGpPWpGaD
Orlistat—DAGLA—G alpha (q) signalling events—TRPC6—focal segmental glomerulosclerosis	0.00425	0.00791	CbGpPWpGaD
Orlistat—PNLIP—Lipid and lipoprotein metabolism—ALB—focal segmental glomerulosclerosis	0.00417	0.00778	CbGpPWpGaD
Orlistat—Increased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.00409	0.00941	CcSEcCtD
Orlistat—Menopausal symptoms—Cyclosporine—focal segmental glomerulosclerosis	0.00407	0.00937	CcSEcCtD
Orlistat—Dermatitis bullous—Cyclosporine—focal segmental glomerulosclerosis	0.00402	0.00925	CcSEcCtD
Orlistat—DAGLB—Hemostasis—ACTN4—focal segmental glomerulosclerosis	0.00399	0.00744	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—ACTN4—focal segmental glomerulosclerosis	0.00399	0.00744	CbGpPWpGaD
Orlistat—Arthritis—Cyclosporine—focal segmental glomerulosclerosis	0.00395	0.00909	CcSEcCtD
Orlistat—Hypoglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00393	0.00906	CcSEcCtD
Orlistat—Osteoarthritis—Cyclosporine—focal segmental glomerulosclerosis	0.00384	0.00884	CcSEcCtD
Orlistat—PNLIP—Diseases associated with visual transduction—LPL—focal segmental glomerulosclerosis	0.0038	0.00709	CbGpPWpGaD
Orlistat—DAGLB—Gastrin-CREB signalling pathway via PKC and MAPK—TRPC6—focal segmental glomerulosclerosis	0.0038	0.00708	CbGpPWpGaD
Orlistat—DAGLA—Gastrin-CREB signalling pathway via PKC and MAPK—TRPC6—focal segmental glomerulosclerosis	0.0038	0.00708	CbGpPWpGaD
Orlistat—PLA2G4A—Signal amplification—GNAQ—focal segmental glomerulosclerosis	0.00376	0.00701	CbGpPWpGaD
Orlistat—DAGLB—Platelet activation, signaling and aggregation—TRPC6—focal segmental glomerulosclerosis	0.00372	0.00692	CbGpPWpGaD
Orlistat—DAGLA—Platelet activation, signaling and aggregation—TRPC6—focal segmental glomerulosclerosis	0.00372	0.00692	CbGpPWpGaD
Orlistat—DAGLB—G alpha (q) signalling events—GNAQ—focal segmental glomerulosclerosis	0.00355	0.00661	CbGpPWpGaD
Orlistat—DAGLA—G alpha (q) signalling events—GNAQ—focal segmental glomerulosclerosis	0.00355	0.00661	CbGpPWpGaD
Orlistat—Dry skin—Cyclosporine—focal segmental glomerulosclerosis	0.00352	0.0081	CcSEcCtD
Orlistat—Abdominal pain upper—Cyclosporine—focal segmental glomerulosclerosis	0.00351	0.00807	CcSEcCtD
Orlistat—FASN—SREBP signalling—LPL—focal segmental glomerulosclerosis	0.00348	0.00648	CbGpPWpGaD
Orlistat—Breast disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00347	0.00799	CcSEcCtD
Orlistat—Cramp muscle—Cyclosporine—focal segmental glomerulosclerosis	0.00346	0.00796	CcSEcCtD
Orlistat—Gastritis—Cyclosporine—focal segmental glomerulosclerosis	0.0034	0.00782	CcSEcCtD
Orlistat—Abdominal distension—Cyclosporine—focal segmental glomerulosclerosis	0.00334	0.00769	CcSEcCtD
Orlistat—FASN—Integration of energy metabolism—GNAQ—focal segmental glomerulosclerosis	0.00333	0.0062	CbGpPWpGaD
Orlistat—Bronchospasm—Cyclosporine—focal segmental glomerulosclerosis	0.00326	0.00751	CcSEcCtD
Orlistat—Pancreatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00325	0.00749	CcSEcCtD
Orlistat—DAGLA—G alpha (q) signalling events—AGTR1—focal segmental glomerulosclerosis	0.00325	0.00605	CbGpPWpGaD
Orlistat—DAGLB—G alpha (q) signalling events—AGTR1—focal segmental glomerulosclerosis	0.00325	0.00605	CbGpPWpGaD
Orlistat—Sweating increased—Cyclosporine—focal segmental glomerulosclerosis	0.00323	0.00744	CcSEcCtD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—ACTA2—focal segmental glomerulosclerosis	0.00319	0.00595	CbGpPWpGaD
Orlistat—Abdominal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00318	0.00732	CcSEcCtD
Orlistat—DAGLA—Gastrin-CREB signalling pathway via PKC and MAPK—GNAQ—focal segmental glomerulosclerosis	0.00317	0.00592	CbGpPWpGaD
Orlistat—DAGLB—Gastrin-CREB signalling pathway via PKC and MAPK—GNAQ—focal segmental glomerulosclerosis	0.00317	0.00592	CbGpPWpGaD
Orlistat—DAGLB—Platelet activation, signaling and aggregation—GNAQ—focal segmental glomerulosclerosis	0.00311	0.00579	CbGpPWpGaD
Orlistat—DAGLA—Platelet activation, signaling and aggregation—GNAQ—focal segmental glomerulosclerosis	0.00311	0.00579	CbGpPWpGaD
Orlistat—Upper respiratory tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.00308	0.0071	CcSEcCtD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—ACTN4—focal segmental glomerulosclerosis	0.00307	0.00573	CbGpPWpGaD
Orlistat—PLA2G4A—Prostaglandin Synthesis and Regulation—EDN1—focal segmental glomerulosclerosis	0.00299	0.00558	CbGpPWpGaD
Orlistat—Infestation NOS—Cyclosporine—focal segmental glomerulosclerosis	0.00296	0.00681	CcSEcCtD
Orlistat—Infestation—Cyclosporine—focal segmental glomerulosclerosis	0.00296	0.00681	CcSEcCtD
Orlistat—Depression—Cyclosporine—focal segmental glomerulosclerosis	0.00295	0.00679	CcSEcCtD
Orlistat—Renal failure—Cyclosporine—focal segmental glomerulosclerosis	0.00291	0.00669	CcSEcCtD
Orlistat—DAGLB—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—focal segmental glomerulosclerosis	0.0029	0.00541	CbGpPWpGaD
Orlistat—DAGLA—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—focal segmental glomerulosclerosis	0.0029	0.00541	CbGpPWpGaD
Orlistat—Neuropathy peripheral—Cyclosporine—focal segmental glomerulosclerosis	0.0029	0.00668	CcSEcCtD
Orlistat—Urinary tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.00288	0.00662	CcSEcCtD
Orlistat—PLA2G4A—cortex of kidney—focal segmental glomerulosclerosis	0.00287	0.0995	CbGeAlD
Orlistat—Hepatobiliary disease—Cyclosporine—focal segmental glomerulosclerosis	0.0028	0.00644	CcSEcCtD
Orlistat—Sinusitis—Cyclosporine—focal segmental glomerulosclerosis	0.00278	0.00639	CcSEcCtD
Orlistat—DAGLB—G alpha (q) signalling events—EDN1—focal segmental glomerulosclerosis	0.00275	0.00513	CbGpPWpGaD
Orlistat—DAGLA—G alpha (q) signalling events—EDN1—focal segmental glomerulosclerosis	0.00275	0.00513	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—ANGPT2—focal segmental glomerulosclerosis	0.00267	0.00498	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—ANGPT2—focal segmental glomerulosclerosis	0.00267	0.00498	CbGpPWpGaD
Orlistat—Haemoglobin—Cyclosporine—focal segmental glomerulosclerosis	0.00267	0.00614	CcSEcCtD
Orlistat—Hepatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00266	0.00611	CcSEcCtD
Orlistat—Haemorrhage—Cyclosporine—focal segmental glomerulosclerosis	0.00266	0.00611	CcSEcCtD
Orlistat—Pharyngitis—Cyclosporine—focal segmental glomerulosclerosis	0.00264	0.00607	CcSEcCtD
Orlistat—Urinary tract disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00262	0.00604	CcSEcCtD
Orlistat—Urethral disorder—Cyclosporine—focal segmental glomerulosclerosis	0.0026	0.00599	CcSEcCtD
Orlistat—PLA2G4A—Endothelins—TRPC6—focal segmental glomerulosclerosis	0.00255	0.00475	CbGpPWpGaD
Orlistat—DAGLA—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—focal segmental glomerulosclerosis	0.00246	0.00459	CbGpPWpGaD
Orlistat—DAGLB—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—focal segmental glomerulosclerosis	0.00246	0.00459	CbGpPWpGaD
Orlistat—Mediastinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00239	0.00551	CcSEcCtD
Orlistat—Alopecia—Cyclosporine—focal segmental glomerulosclerosis	0.00235	0.0054	CcSEcCtD
Orlistat—FASN—Fatty acid, triacylglycerol, and ketone body metabolism—CTGF—focal segmental glomerulosclerosis	0.00233	0.00434	CbGpPWpGaD
Orlistat—Mental disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00233	0.00536	CcSEcCtD
Orlistat—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.00231	0.00532	CcSEcCtD
Orlistat—DAGLB—G alpha (q) signalling events—AGT—focal segmental glomerulosclerosis	0.00228	0.00426	CbGpPWpGaD
Orlistat—DAGLA—G alpha (q) signalling events—AGT—focal segmental glomerulosclerosis	0.00228	0.00426	CbGpPWpGaD
Orlistat—Flatulence—Cyclosporine—focal segmental glomerulosclerosis	0.00228	0.00524	CcSEcCtD
Orlistat—Dysgeusia—Cyclosporine—focal segmental glomerulosclerosis	0.00226	0.00521	CcSEcCtD
Orlistat—Muscle spasms—Cyclosporine—focal segmental glomerulosclerosis	0.00222	0.00512	CcSEcCtD
Orlistat—Vision blurred—Cyclosporine—focal segmental glomerulosclerosis	0.00218	0.00502	CcSEcCtD
Orlistat—PLA2G4A—Platelet homeostasis—TRPC6—focal segmental glomerulosclerosis	0.00215	0.00401	CbGpPWpGaD
Orlistat—Ill-defined disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00215	0.00494	CcSEcCtD
Orlistat—PLA2G4A—Endothelins—GNAQ—focal segmental glomerulosclerosis	0.00213	0.00397	CbGpPWpGaD
Orlistat—Angioedema—Cyclosporine—focal segmental glomerulosclerosis	0.00211	0.00486	CcSEcCtD
Orlistat—Malaise—Cyclosporine—focal segmental glomerulosclerosis	0.00209	0.0048	CcSEcCtD
Orlistat—Vertigo—Cyclosporine—focal segmental glomerulosclerosis	0.00208	0.00478	CcSEcCtD
Orlistat—FASN—p73 transcription factor network—SERPINE1—focal segmental glomerulosclerosis	0.00205	0.00382	CbGpPWpGaD
Orlistat—DAGLA—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—focal segmental glomerulosclerosis	0.00204	0.00381	CbGpPWpGaD
Orlistat—DAGLB—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—focal segmental glomerulosclerosis	0.00204	0.00381	CbGpPWpGaD
Orlistat—Cough—Cyclosporine—focal segmental glomerulosclerosis	0.00202	0.00464	CcSEcCtD
Orlistat—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—NOS2—focal segmental glomerulosclerosis	0.00201	0.00374	CbGpPWpGaD
Orlistat—Convulsion—Cyclosporine—focal segmental glomerulosclerosis	0.002	0.00461	CcSEcCtD
Orlistat—Chest pain—Cyclosporine—focal segmental glomerulosclerosis	0.00197	0.00453	CcSEcCtD
Orlistat—Myalgia—Cyclosporine—focal segmental glomerulosclerosis	0.00197	0.00453	CcSEcCtD
Orlistat—Anxiety—Cyclosporine—focal segmental glomerulosclerosis	0.00196	0.00452	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.00196	0.0045	CcSEcCtD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—ACTN4—focal segmental glomerulosclerosis	0.00195	0.00363	CbGpPWpGaD
Orlistat—Discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00195	0.00448	CcSEcCtD
Orlistat—Dry mouth—Cyclosporine—focal segmental glomerulosclerosis	0.00193	0.00443	CcSEcCtD
Orlistat—DAGLA—Hemostasis—TRPC6—focal segmental glomerulosclerosis	0.00192	0.00357	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—TRPC6—focal segmental glomerulosclerosis	0.00192	0.00357	CbGpPWpGaD
Orlistat—Anaphylactic shock—Cyclosporine—focal segmental glomerulosclerosis	0.00189	0.00434	CcSEcCtD
Orlistat—Oedema—Cyclosporine—focal segmental glomerulosclerosis	0.00189	0.00434	CcSEcCtD
Orlistat—Infection—Cyclosporine—focal segmental glomerulosclerosis	0.00187	0.00432	CcSEcCtD
Orlistat—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00185	0.00426	CcSEcCtD
Orlistat—DAGLA—Platelet activation, signaling and aggregation—FN1—focal segmental glomerulosclerosis	0.00185	0.00344	CbGpPWpGaD
Orlistat—DAGLB—Platelet activation, signaling and aggregation—FN1—focal segmental glomerulosclerosis	0.00185	0.00344	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—PIAS1—focal segmental glomerulosclerosis	0.00184	0.00343	CbGpPWpGaD
Orlistat—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00183	0.00422	CcSEcCtD
Orlistat—Hyperhidrosis—Cyclosporine—focal segmental glomerulosclerosis	0.00182	0.0042	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00172	0.00396	CcSEcCtD
Orlistat—Insomnia—Cyclosporine—focal segmental glomerulosclerosis	0.00171	0.00393	CcSEcCtD
Orlistat—Paraesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.00169	0.0039	CcSEcCtD
Orlistat—PLA2G7—Metabolism of proteins—ACE—focal segmental glomerulosclerosis	0.00169	0.00314	CbGpPWpGaD
Orlistat—Dyspepsia—Cyclosporine—focal segmental glomerulosclerosis	0.00166	0.00382	CcSEcCtD
Orlistat—PLA2G4A—Endothelins—EDN1—focal segmental glomerulosclerosis	0.00165	0.00308	CbGpPWpGaD
Orlistat—Decreased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.00164	0.00378	CcSEcCtD
Orlistat—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00163	0.00375	CcSEcCtD
Orlistat—Fatigue—Cyclosporine—focal segmental glomerulosclerosis	0.00163	0.00374	CcSEcCtD
Orlistat—Pain—Cyclosporine—focal segmental glomerulosclerosis	0.00161	0.00371	CcSEcCtD
Orlistat—DAGLB—Hemostasis—GNAQ—focal segmental glomerulosclerosis	0.0016	0.00298	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—GNAQ—focal segmental glomerulosclerosis	0.0016	0.00298	CbGpPWpGaD
Orlistat—Feeling abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.00156	0.00358	CcSEcCtD
Orlistat—Gastrointestinal pain—Cyclosporine—focal segmental glomerulosclerosis	0.00154	0.00355	CcSEcCtD
Orlistat—DAGLA—Platelet activation, signaling and aggregation—SERPINE1—focal segmental glomerulosclerosis	0.00154	0.00286	CbGpPWpGaD
Orlistat—DAGLB—Platelet activation, signaling and aggregation—SERPINE1—focal segmental glomerulosclerosis	0.00154	0.00286	CbGpPWpGaD
Orlistat—DAGLB—Platelet activation, signaling and aggregation—ALB—focal segmental glomerulosclerosis	0.00153	0.00286	CbGpPWpGaD
Orlistat—DAGLA—Platelet activation, signaling and aggregation—ALB—focal segmental glomerulosclerosis	0.00153	0.00286	CbGpPWpGaD
Orlistat—Urticaria—Cyclosporine—focal segmental glomerulosclerosis	0.0015	0.00345	CcSEcCtD
Orlistat—Abdominal pain—Cyclosporine—focal segmental glomerulosclerosis	0.00149	0.00343	CcSEcCtD
Orlistat—Body temperature increased—Cyclosporine—focal segmental glomerulosclerosis	0.00149	0.00343	CcSEcCtD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	0.00149	0.00277	CbGpPWpGaD
Orlistat—Hypersensitivity—Cyclosporine—focal segmental glomerulosclerosis	0.00139	0.0032	CcSEcCtD
Orlistat—FASN—Fatty acid, triacylglycerol, and ketone body metabolism—AGT—focal segmental glomerulosclerosis	0.00138	0.00257	CbGpPWpGaD
Orlistat—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.00135	0.00312	CcSEcCtD
Orlistat—Pruritus—Cyclosporine—focal segmental glomerulosclerosis	0.00134	0.00307	CcSEcCtD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	0.00131	0.00244	CbGpPWpGaD
Orlistat—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.00129	0.00297	CcSEcCtD
Orlistat—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.00125	0.00287	CcSEcCtD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—WT1—focal segmental glomerulosclerosis	0.00121	0.00226	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	0.00121	0.00225	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	0.00121	0.00225	CbGpPWpGaD
Orlistat—PLA2G4A—AGE/RAGE pathway—NOS2—focal segmental glomerulosclerosis	0.00121	0.00225	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	0.0012	0.00224	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	0.0012	0.00224	CbGpPWpGaD
Orlistat—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	0.0012	0.00276	CcSEcCtD
Orlistat—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.00119	0.00274	CcSEcCtD
Orlistat—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00119	0.00274	CcSEcCtD
Orlistat—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.00118	0.00272	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	0.00114	0.00212	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	0.00114	0.00212	CbGpPWpGaD
Orlistat—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.00112	0.00258	CcSEcCtD
Orlistat—DAGLB—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	0.0011	0.00205	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	0.0011	0.00205	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	0.00109	0.00204	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	0.00109	0.00204	CbGpPWpGaD
Orlistat—PLA2G7—Metabolism of proteins—AGT—focal segmental glomerulosclerosis	0.00107	0.00199	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet homeostasis—NOS2—focal segmental glomerulosclerosis	0.00106	0.00197	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	0.00105	0.00196	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	0.00104	0.00195	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	0.00104	0.00195	CbGpPWpGaD
Orlistat—PLA2G4A—AGE/RAGE pathway—MMP2—focal segmental glomerulosclerosis	0.00104	0.00193	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	0.00101	0.00189	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	0.00101	0.00189	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—ACTN4—focal segmental glomerulosclerosis	0.001	0.00187	CbGpPWpGaD
Orlistat—CYP3A4—kidney—focal segmental glomerulosclerosis	0.000971	0.0337	CbGeAlD
Orlistat—DAGLB—Platelet activation, signaling and aggregation—TGFB1—focal segmental glomerulosclerosis	0.00097	0.00181	CbGpPWpGaD
Orlistat—DAGLA—Platelet activation, signaling and aggregation—TGFB1—focal segmental glomerulosclerosis	0.00097	0.00181	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—FN1—focal segmental glomerulosclerosis	0.000952	0.00177	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—FN1—focal segmental glomerulosclerosis	0.000952	0.00177	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	0.000942	0.00176	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—NOS2—focal segmental glomerulosclerosis	0.000941	0.00175	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—NOS2—focal segmental glomerulosclerosis	0.000941	0.00175	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—TRPC6—focal segmental glomerulosclerosis	0.000935	0.00174	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	0.000927	0.00173	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	0.000925	0.00172	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	0.000925	0.00172	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	0.000919	0.00171	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	0.000919	0.00171	CbGpPWpGaD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	0.000909	0.00169	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.000883	0.00164	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.000883	0.00164	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	0.000866	0.00161	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	0.00084	0.00157	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	0.00084	0.00157	CbGpPWpGaD
Orlistat—PLA2G7—Metabolism of proteins—MMP2—focal segmental glomerulosclerosis	0.000838	0.00156	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	0.000792	0.00148	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	0.000792	0.00148	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—ALB—focal segmental glomerulosclerosis	0.000791	0.00147	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—ALB—focal segmental glomerulosclerosis	0.000791	0.00147	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	0.000784	0.00146	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	0.000784	0.00146	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—GNAQ—focal segmental glomerulosclerosis	0.000781	0.00146	CbGpPWpGaD
Orlistat—PLA2G4A—AGE/RAGE pathway—MMP9—focal segmental glomerulosclerosis	0.000779	0.00145	CbGpPWpGaD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	0.000777	0.00145	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.000732	0.00136	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	0.000712	0.00133	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	0.000712	0.00133	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—ANGPT2—focal segmental glomerulosclerosis	0.000672	0.00125	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—LIPC—focal segmental glomerulosclerosis	0.000663	0.00124	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	0.000651	0.00121	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	0.000651	0.00121	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	0.000649	0.00121	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	0.000649	0.00121	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	0.000646	0.0012	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	0.000646	0.0012	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	0.000643	0.0012	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—PCNA—focal segmental glomerulosclerosis	0.000614	0.00114	CbGpPWpGaD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	0.000596	0.00111	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	0.000591	0.0011	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	0.000591	0.0011	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—CTGF—focal segmental glomerulosclerosis	0.000584	0.00109	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	0.00055	0.00102	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	0.000543	0.00101	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	0.000543	0.00101	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	0.000538	0.001	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—GNAQ—focal segmental glomerulosclerosis	0.000538	0.001	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	0.000535	0.000997	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—TGFB1—focal segmental glomerulosclerosis	0.0005	0.000932	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—TGFB1—focal segmental glomerulosclerosis	0.0005	0.000932	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	0.000496	0.000925	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	0.000496	0.000925	CbGpPWpGaD
Orlistat—PNLIP—Disease—LPL—focal segmental glomerulosclerosis	0.000483	0.0009	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—TRPC6—focal segmental glomerulosclerosis	0.000482	0.000898	CbGpPWpGaD
Orlistat—FASN—Metabolism—LIPC—focal segmental glomerulosclerosis	0.000469	0.000874	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—FN1—focal segmental glomerulosclerosis	0.000465	0.000866	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	0.000452	0.000842	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	0.00045	0.000838	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	0.000422	0.000786	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	0.000421	0.000784	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	0.000421	0.000784	CbGpPWpGaD
Orlistat—FASN—Metabolism—CTGF—focal segmental glomerulosclerosis	0.000413	0.000769	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	0.000411	0.000766	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—LPL—focal segmental glomerulosclerosis	0.000408	0.000761	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—LPL—focal segmental glomerulosclerosis	0.000408	0.000761	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—LPL—focal segmental glomerulosclerosis	0.000405	0.000754	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—GNAQ—focal segmental glomerulosclerosis	0.000403	0.00075	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	0.000398	0.000741	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	0.000387	0.000721	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	0.000387	0.000721	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—SERPINE1—focal segmental glomerulosclerosis	0.000387	0.00072	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—ALB—focal segmental glomerulosclerosis	0.000386	0.000719	CbGpPWpGaD
Orlistat—FASN—Metabolism—GNAQ—focal segmental glomerulosclerosis	0.000381	0.000709	CbGpPWpGaD
Orlistat—PNLIP—Disease—NOS2—focal segmental glomerulosclerosis	0.000377	0.000703	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—AGT—focal segmental glomerulosclerosis	0.000349	0.000651	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—AGT—focal segmental glomerulosclerosis	0.000349	0.000651	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	0.000349	0.00065	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—AGT—focal segmental glomerulosclerosis	0.000346	0.000645	CbGpPWpGaD
Orlistat—FASN—Disease—LPL—focal segmental glomerulosclerosis	0.000342	0.000637	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—LPL—focal segmental glomerulosclerosis	0.000338	0.00063	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—FN1—focal segmental glomerulosclerosis	0.000323	0.000601	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—FN1—focal segmental glomerulosclerosis	0.000323	0.000601	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	0.00032	0.000597	CbGpPWpGaD
Orlistat—PNLIP—Disease—SERPINE1—focal segmental glomerulosclerosis	0.000318	0.000592	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—AGT—focal segmental glomerulosclerosis	0.000289	0.000539	CbGpPWpGaD
Orlistat—FASN—Metabolism—LPL—focal segmental glomerulosclerosis	0.000286	0.000533	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	0.000286	0.000533	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	0.000276	0.000515	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	0.000276	0.000514	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	0.000275	0.000512	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	0.000274	0.000511	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	0.000269	0.0005	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	0.000269	0.0005	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—FN1—focal segmental glomerulosclerosis	0.000267	0.000498	CbGpPWpGaD
Orlistat—FASN—Disease—NOS2—focal segmental glomerulosclerosis	0.000267	0.000497	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—ALB—focal segmental glomerulosclerosis	0.000266	0.000495	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	0.000263	0.00049	CbGpPWpGaD
Orlistat—FASN—Metabolism—AGT—focal segmental glomerulosclerosis	0.000245	0.000456	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—TGFB1—focal segmental glomerulosclerosis	0.000244	0.000455	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—FN1—focal segmental glomerulosclerosis	0.00024	0.000446	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—NOS2—focal segmental glomerulosclerosis	0.000237	0.000441	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	0.000236	0.00044	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	0.000231	0.000431	CbGpPWpGaD
Orlistat—FASN—Disease—SERPINE1—focal segmental glomerulosclerosis	0.000225	0.000419	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	0.000223	0.000415	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.000222	0.000414	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	0.000211	0.000394	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	0.000206	0.000383	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	0.000206	0.000383	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—LIPC—focal segmental glomerulosclerosis	0.000201	0.000375	CbGpPWpGaD
Orlistat—PNLIP—Disease—TGFB1—focal segmental glomerulosclerosis	0.000201	0.000374	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	0.000199	0.000371	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—ALB—focal segmental glomerulosclerosis	0.000199	0.000371	CbGpPWpGaD
Orlistat—FASN—Metabolism—ALB—focal segmental glomerulosclerosis	0.000188	0.00035	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	0.000181	0.000337	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	0.000179	0.000334	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CTGF—focal segmental glomerulosclerosis	0.000177	0.00033	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	0.00017	0.000318	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	0.00017	0.000316	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	0.00017	0.000316	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	0.000163	0.000304	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GNAQ—focal segmental glomerulosclerosis	0.000163	0.000304	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	0.000162	0.000303	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	0.000149	0.000277	CbGpPWpGaD
Orlistat—FASN—Disease—TGFB1—focal segmental glomerulosclerosis	0.000142	0.000264	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	0.00014	0.000262	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	0.000137	0.000254	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—TGFB1—focal segmental glomerulosclerosis	0.000126	0.000234	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	0.000125	0.000233	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—LPL—focal segmental glomerulosclerosis	0.000123	0.000229	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	0.000106	0.000197	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—AGT—focal segmental glomerulosclerosis	0.000105	0.000196	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—LPL—focal segmental glomerulosclerosis	0.000103	0.000191	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	9.73e-05	0.000181	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AGT—focal segmental glomerulosclerosis	8.79e-05	0.000164	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FN1—focal segmental glomerulosclerosis	8.12e-05	0.000151	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ALB—focal segmental glomerulosclerosis	8.06e-05	0.00015	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	6.76e-05	0.000126	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	5.18e-05	9.64e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—LIPC—focal segmental glomerulosclerosis	4.71e-05	8.78e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	4.27e-05	7.95e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CTGF—focal segmental glomerulosclerosis	4.15e-05	7.73e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GNAQ—focal segmental glomerulosclerosis	3.82e-05	7.13e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—LPL—focal segmental glomerulosclerosis	2.88e-05	5.36e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—AGT—focal segmental glomerulosclerosis	2.46e-05	4.59e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ALB—focal segmental glomerulosclerosis	1.89e-05	3.52e-05	CbGpPWpGaD
